NT-proBNP as an Additional Marker of Significant Coronary Atherosclerotic Lesions

DOI: https://doi.org/10.30702/ujcvs/21.4512/MR057-4349
Keywords: coronary artery disease, homocysteine, body mass index, NT-proBNP, multivessel disease, SYNTAX Score

Abstract

Coronary artery disease (CAD) is the leading cause for morbidity and mortality both in Ukraine and in the world, so the relevance of this problem for the society is undeniable. The priority is still to study the factors that affect both more severe CAD in patients with chronic coronary syndrome and after myocardial revascularization.

The aim. To investigate the patterns of correlation between blood level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CAD severity, especially in patients with multivessel lesion, to confirm its status of a useful additional marker for assessing the condition of cardiovascular system and one of the instruments to affect the tactics of treatment.

Materials and methods. The study is based on data obtained from a prospective analysis of 40 patients at the age of 51 to 82 years old from January to December 2019, whose complaints could indicate the CAD. All the patients underwent a comprehensive clinical and laboratory examination (complete blood count, biochemical blood test). The main instrumental examination method was coronary angiography; the patients were divided into 2 groups on the basis of the examination results. The quantitative degree of lesion was assessed using the SYNTAX Score for each patient.

Results. The groups were comparable in terms of age, sex, and comorbidities. The groups differed significantly in terms of body mass index. Moreover, the groups differed in the level of the following biochemical markers: NT-proBNP (p=0.0001), cholesterol (p=0.02), low-density lipoproteins (p=0.009), creatinine (p=0.02), glomerular filtration rate (p=0.08). A significant correlation was found between the NT-proBNP level and the degree of CAD ρ=0.718 (p=0.0001).

Conclusion. NT-proBNP significantly correlates with the SYNTAX Score and is the highest in the group of patients with multivessel coronary disease. This indicator requires further study as an additional marker for assessing the state of the cardiovascular system and can influence the choice of treatment.

References

  1. Antomonov MYu. Matematicheskaya obrabotka i analiz mediko-biologicheskikh dannykh [Mathematical processing and analysis of biomedical data]. 2nd ed. Kyiv: Medinform;2018. p. 576. Russian.
  2. Voronkov LG. [Guidelines of the Ukraine Association of Cardiology for the Diagnosis and Treatment of Chronic Heart Failure]. Ukrainian Journal of Cardiology. 2018;25(3):11-59. Ukrainian.
  3. Daiber A, Steven S, Weber A, Shuvaev VV, Muzykantov VR, Laher I, Li H, Lamas S, Münzel T. Targeting vascular (endothelial) dysfunction. Br J Pharmacol. 2017;174(12):1591-619. https://doi.org/10.1111/bph.13517
  4. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89-94. https://doi.org/10.1016/0024-3205(81)90370-2
  5. WHO [Internet]. WHO;2018 [cited 2021 Oct 27]. Global Health Observatory (GHO) data. Top 10 causes of death, situation and trends. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death
  6. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8):CD006612. https://doi.org/10.1002/14651858.CD006612.pub5
  7. Michou E, Fahrni G, Mueller C. Quantifying heart failure using natriuretic peptides may help the HEART teamin decision-making. Eur Heart J. 2019;40(41):3406-8.https://doi.org/10.1093/eurheartj/ehz572
  8. Oemrawsingh RM, Akkerhuis KM, de Mulder M, Umans VA,Kietselaer B, Schotborgh C, et al. High-frequency biomarker measurements of troponin, NT-proBNP, and C-reactive protein for prediction of new coronary events after acute coronary syndrome. Circulation. 2019;139(1):134-6.https://doi.org/10.1161/CIRCULATIONAHA.118.036349
  9. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. https://doi.org/10.1002/ejhf.592
  10. Reboldi G, Verdecchia P, Fiorucci G, Beilin LJ, Eguchi K, Imai Y, Kario K, Ohkubo T, Pierdomenico SD, Schwartz JE, Wing L, Saladini F, Palatini P. Glomerular hyperfiltration is a predictor of adverse cardiovascular outcomes. Kidney Int. 2018;93(1):195-203. https://doi.org/10.1016/j.kint.2017.07.013
  11. Redfors B, Chen S, Crowley A, Ben-Yehuda O, Gersh BJ, Lembo NJ, Brown WM 3rd, Banning AP, Taggart DP, Serruys PW, Kappetein AP, Sabik JF 3rd, Stone GW. B-type natriuretic peptide assessment in patients undergoing revascularization for left main coronary artery disease: analysis from the EXCEL trial. Circulation. 2018;138(5):469-78. https://doi.org/10.1161/CIRCULATIONAHA.118.033631
  12. Gulati R, Rihal CS, Gersh BJ. The SYNTAX trial: a perspective. Circ Cardiovasc Interv. 2009;2(5):463-7. https://doi.org/10.1161/CIRCINTERVENTIONS.109.882670
  13. Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, Matsuo S, Imai E, Makino H, Hishida A; CKD-JAC Investigators. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91(1):227-34. https://doi.org/10.1016/j.kint.2016.09.015
  14. Zhuang Q, Shen C, Chen Y, Zhao X, Wei P, Sun J, Ji Y, Chen X, Yang S. Association of high sensitive C-reactive protein with coronary heart disease: a Mendelian randomization study. BMC Med Genet. 2019;20(1):170. https://doi.org/10.1186/s12881-019-0910-z
Published
2021-12-22
How to Cite
1.
Marchenko OY, Rudenko NM, Dzhun YY. NT-proBNP as an Additional Marker of Significant Coronary Atherosclerotic Lesions. ujcvs [Internet]. 2021Dec.22 [cited 2024Dec.26];(4 (45):43-9. Available from: http://cvs.org.ua/index.php/ujcvs/article/view/448
Issue
Ukrainian Journal of Cardiovascular Surgery No 4 (45) 2021
Section
ISCHEMIC HEART DISEASE